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Autoantibody production is a characteristic of most autoimmune diseases including 
rheumatoid arthritis (RA). The role of these autoantibodies in the pathogenesis of RA 
remains elusive, but they appear in the serum many years before the onset of clinical disease 
suggesting an early break in B cell tolerance. The stage of B cell development at which B cell 
tolerance is broken in RA remains unknown. We previously established in healthy donors 
that most polyreactive developing B cells are silenced in the bone marrow, and additional 
autoreactive B cells are removed in the periphery. B cell tolerance in untreated active RA 
patients was analyzed by testing the specificity of recombinant antibodies cloned from 
single B cells. We find that autoreactive B cells fail to be removed in all six RA patients and 
represent 35–52% of the mature naive B cell compartment compared with 20% in healthy 
donors. In some patients, RA B cells express an increased proportion of polyreactive 
antibodies that can recognize immunoglobulins and cyclic citrullinated peptides, suggesting 
early defects in central B cell tolerance. Thus, RA patients exhibit defective B cell tolerance 
checkpoints that may favor the development of autoimmunity.
 
Rheumatoid arthritis (RA) is a common
chronic inflammatory disease that affects 
 
 
 
1%
of the population (1). An important character-
istic that distinguishes RA from other inflam-
matory and degenerative joint diseases is the
production of autoantibodies directed against
self-antigens including antibody Fc regions
(rheumatoid factors), type II collagen, and cy-
clic citrullinated peptides (CCP; 2–5). These
antibodies appear in the serum of RA patients
many years before the onset of clinical disease
suggesting an early break in B cell tolerance
(6). However, the underlying mechanisms
that account for autoantibody production in
RA have not been defined. Mouse models re-
veal an important role for T and B cells in the
development of inflammatory arthritis (7, 8).
In humans, an important role for B cells in
RA was recently demonstrated by successful
treatment of RA patients with anti-CD20
monoclonal antibodies that eliminate B cells
(9, 10). Although little is known about the
characteristics of RA B cells, some express un-
usual B cell receptors (BCRs) with 11–amino
acid–long CDR3 Ig
 
 
 
 chains that accumulate
in the joints of RA patients (11, 12). It is un-
clear if those unusual BCRs result from al-
tered B cell development and reflect impaired
B cell tolerance.
We previously analyzed how B cell toler-
ance was established in humans by following
the evolution of autoantibody-producing B
cells during B cell development (13). Using an
RT-PCR method that allowed us to clone
and express in vitro recombinant antibodies
amplified from single B cells, we found that
55–75% of early B cell precursors expressed
self-reactive antibodies and that autoantibody-
producing B cells in healthy donors were re-
moved from the population at two discrete
checkpoints (13). The first checkpoint occurs
in the bone marrow between the early imma-
ture and immature B cell stage. The second
counterselection step of autoantibody-express-
ing B cells takes place in the periphery, at the
transition from new emigrant to mature naive
B cells (13). We applied the same method to
characterize how B cell tolerance was estab-
lished in RA patients. We found that central
and peripheral B cell tolerance checkpoints
were defective in RA patients and allowed the
accumulation of peripheral mature naive au-
toreactive B cells that may contribute to RA
pathogenesis.
 
The online version of this article contains supplemental material.
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agammaglobulinemia. 
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RESULTS
 
To determine whether B cell tolerance is established properly in
RA patients, we enrolled nine active RA patients who met the
Revised Criteria of the American College of Rheumatology
and examined the reactivity of antibodies from six of them (Ta-
ble I). Eight patients were either naive to steroids, disease-mod-
ifying antirheumatic drugs, and biologics, or off these medica-
tions for at least 4 mo (see Materials and methods and Table I).
Only patient RA07 had been taking hydroxychloroquine for
2 mo before the day when blood was drawn. In total, we
cloned and expressed in vitro 176 and 177 antibodies from sin-
gle new emigrant (CD19
 
 
 
CD10
 
 
 
IgM
 
 
 
CD27
 
 
 
) and mature
naive (CD19
 
 
 
CD10
 
 
 
IgM
 
 
 
CD27
 
 
 
) RA B cells, respectively,
and compared them to control antibodies from four previously
reported and three additional healthy donors (Table S1 available
at http://www.jem.org/cgi/content/full/jem.20042321/DC1;
13–15).
 
RA new emigrant B cells express remarkable
antibody repertoires
 
The B cells from our nine patients revealed at least three dis-
tinct patterns of antibody sequences. Consistent with previ-
ous reports on RA, the proportion of Ig
 
 
 
s with unusual
 
 
 
11–amino acid–long CDR3s in new emigrant B cells was
significantly increased from 0 to 4.1% in controls to 5.7 to
17.9% in RA patients (P 
 
  
 
0.0008, Fig. 1 and Tables
S2–S16 available at http://www.jem.org/cgi/content/full/
jem.20042321/DC1; 11, 12). The Ig
 
 
 
 antibody repertoires
of RA01, RA02, and RA08 new emigrant B cells were also
remarkable in that they displayed significantly increased up-
stream J
 
 
 
1 usage (RA01: 53.1%, P 
 
  
 
0.025; RA02: 51.4%,
P 
 
  
 
0.02; and RA08: 47.9%, P 
 
  
 
0.027; Fig. 2 A). In con-
trast, J
 
 
 
1 usage frequency in new emigrant B cells from
seven control healthy donors and from the other RA pa-
tients ranged from 21 to 36% and 21 to 41%, respectively
(Fig. 2 A; 13, 14). J
 
 
 
1 Ig segment is eliminated when up-
stream V
 
 
 
 genes delete preexisting V
 
 
 
J
 
 
 
1 genes by recom-
bining with downstream J
 
 
 
 genes (16). We found that up-
stream V
 
 
 
 gene usage in new emigrant B cells was decreased
in RA01 (9.5%), RA02 (8.5%, P 
 
  
 
0.044), and RA08
(14.3%) when compared with controls (21–36%; Fig. 2, B
and C). Upstream V
 
 
 
 gene usage was also decreased in
RA01 and RA02 mature naive B cells (RA01: 5.2%, P 
 
 
 
0.0048; RA02: 16.1% P 
 
  
 
0.3 vs. 27.7% in control ma-
ture  naive B cells; Tables S8 and S9 available at http://
www.jem.org/cgi/content/full/jem.20042321/DC1 and
 
Table I.
 
Patient characteristics
 
RA01 RA02 RA03 RA04 RA05 RA06 RA07 RA08 RA09
 
Background black Asian Hispanic white white black black Hispanic Hispanic
Age 60 62 62 36 30 64 44 28 52
Gender F M F F F F F M F
Age RA onset 47 60 59 35 28 62 42 26 51
Years of disease 13 2 3 1 2 2 2 2 1
Joints involved Virtually all Knees, elbows 
wrists, PIPs
IP, MCP, wrists,
elbows, neck,
TMJ
Hands, 
knees
Left wrist, 
ankle
Shoulder, 
right hand, 
diffuse 
arthralgias
Knees, 
hands
Diffuse symmetri-
cal (PIPs, MCPs, 
wrists, knees, 
ankles)
Hands, wrists,
knees, ankles
Prior medication Intermittent
steroids, hydroxy-
chloroquine,
methotrexate
None Steroids, 
methotrexate
None None None Hydroxy-
chloro-
quine (for 
2 mo)
Steroids, hydroxy-
chloroquine, 
methotrexate
None
Months off
DMARDS/steroids
5 NA 4 NA NA NA 0 10 NA
RF
 
 
 
20 848 1,110 55 48 474 267 258 36
Anti-CCP 32 88 240 63
 
 
 
20
 
 
 
250 218 80 150
X-ray erosions
 
        
 
 
 
(by MRI)
 
      
 
 
 
(by ultrasound)
Comorbidities Hypertension Anal fistula, 
cardiomegaly
TB exposure None Childhood 
seizures
Asthma Prior 
cocaine 
use until 
12/03, TB 
exposure
Polysubstance 
abuse on 
methadone
Hypothyroidism,
gastric reflux
Family history
(autoimmune)
 
 
 
Brother with 
“arthritis”
 
 
 
Cousin 
with 
SLE
Father and 
mother with 
thyroid 
disease
Parents 
with 
“arthritis” 
 
  
 
Sister with 
“arthritis”
 
Patients were considered rheumatoid factor or anti-CCP positive when their antibody titers were 
 
 
 
20. DMARDs, disease-modifying anti-rheumatic drugs; CCP, cyclic citrullinated 
peptides; PIPs, proximal interphalangeal joints; IPs, interphalangeal joints; MCPs, metacarpophalangeal joint; TMJ, temporomandibular joint; TB, tuberculosis bacillus. 
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Tables S9 and S10 reported in reference 13). In contrast,
new emigrant B cells from another RA patient, RA06,
showed increased downstream J
 
 
 
3-4-5 combined with up-
stream V
 
 
 
 gene usage (Fig. 2 C). In addition, increased J
 
 
 
1
usage was found in RA patient new emigrant B cells that
displayed the lowest frequency of unusual 
 
 
 
11–amino acid–
long Ig
 
 
 
 CDR3s (Fig. 2 D). We conclude that RA new em-
igrant B cells express at least three distinct patterns of Ig
 
 
 
antibody repertoires: unusually long Ig
 
 
 
 CDR3s, an Ig
 
 
 
repertoire biased toward either upstream J
 
 
 
1 and down-
stream V
 
 
 
 genes or downstream J
 
 
 
3-4-5 and upstream V
 
 
 
genes consistent with decreased or increased secondary
V(D)J recombination, respectively.
 
Defective peripheral B cell tolerance checkpoint 
in RA patients
 
The self-reactivity of the recombinant antibodies from six
RA patients was first tested against HEp-2 cells by ELISA
and indirect immunofluorescence assay (IFA; 13, 17). We
found that the proportion of HEp-2–reactive antibodies in
new emigrant B cells from RA patients ranged from 31.8 to
55.8% (Fig. 3 A) and was not significantly different from that
of control new emigrant antibodies previously reported (31–
40.7%; 13, 14). In contrast, all six RA patients revealed an
increase of HEp-2–reactive mature naive B cells that reached
statistical significance in five of them (Fig. 3 B). In these pa-
tients, mature naive B cells expressing HEp-2–reactive anti-
bodies represented 35.0–51.7%, whereas they only account
for 20.4% of the control mature naive B cell compartment
(RA01: 42.9%, P
 
 
 
  
 
0.026; RA02: 40.0%, P
 
 
 
  
 
0.031;
RA03: 48.4%, P
 
 
 
  
 
0.005; RA04: 51.7%, P
 
 
 
  
 
0.002; RA05:
35.0%, P
 
 
 
  
 
0.24; RA06: 44.8%, P
 
 
 
  
 
0.015; Fig. 3 B). Anti-
bodies from new emigrant and mature naive B cells from
RA patients gave IFA patterns similar to their control coun-
terparts, staining mainly the cytoplasm of HEp-2 cells (un-
published data). We conclude that RA patients fail to re-
move autoreactive B cells in the periphery between the new
emigrant and mature naive B cell stages, revealing a defective
second checkpoint in B cell tolerance.
 
Defective central B cell tolerance checkpoint in RA patients
 
Most polyreactive B cells in healthy donors are removed at a
first checkpoint in the bone marrow between the early im-
mature and immature B cell stage (13). Few low-polyreac-
Figure 1. RA B cells express antibodies with unusually long CDR3s. 
Increased frequency of Ig  genes with unusually long  11 amino acid 
CDR3s in new emigrant B cells from RA patients. Differences in frequency 
of Ig  genes with  11 amino acid CDR3s between healthy donors and 
RA patients were found to be statistically significant (P   0.008).
Figure 2. RA B cells can express an antibody repertoire consistent 
with either decreased or increased secondary V(D)J recombination. 
(A) Increased J 1 usage in new emigrant B cells from RA01, RA02, and 
RA08 patients. Pie charts show the proportion of different J  genes. The 
number of sequences analyzed in each fraction is indicated below the pie 
charts. Control healthy donor new emigrant B cells from HD01, HD02, and 
HD03 were previously reported (13, 14). *, Indicates statistically significant 
difference (RA01: 53.1%, P   0.025; RA02: 51.4%, P   0.02; and RA08: 
47.9%, P   0.027). (B) Decreased upstream (5 ) V  usage in RA01, RA02, 
and RA08 new emigrant B cells. The proximal V  locus involved in 95% of 
V  J  rearrangements is shown clustered into four groups of V  genes. 
Genes from the distal locus were combined to the upstream V  group. The 
percent of each V  group is indicated on the Y axis. *, Indicates statistically 
significant difference (RA02: P   0.044; combined RA01, RA02, RA08: 
P   0.0042). (C) The new emigrant B cell Ig  repertoire in RA06 is consis-
tent with increased secondary V(D)J recombination in developing B cells. 
Patients’ and healthy donor controls’ upstream V  usage frequency was 
plotted against that of downstream J 3-4-5 usage. Increased upstream 
V  usage in RA06 was found to be statistically significant (P   0.033). 
(D) Increased J 1 usage in some RA patients is associated with a lower 
frequency of  11–amino acid–long Ig  CDR3s in new emigrant B cells. 
Patients’ and healthy donor controls’ J 1 usage frequency was plotted 
against that of  11–amino acid–long Ig  CDR3s. 
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tive B cells escape this counterselection step and migrate to
the periphery of healthy donors where they represent 7.4–
9.7% of new emigrant and 4–5% of mature naive B cells (13,
14, 17). To determine whether bone marrow early B cell
tolerance was established properly in RA patients we ana-
lyzed the frequency of polyreactive antibodies in new emi-
grant B cells. We found by ELISA that four out of six
patients showed significantly increased proportions of
polyreactive antibodies in new emigrant B cells (RA01:
26.9%, P
 
 
 
  
 
0.019; RA04: 25.6%, P
 
 
 
  0.014; RA05: 23.8%,
P   0.025; RA06: 27.3%, P   0.025; Fig. 4 A). RA02 and
RA03 new emigrant B cells also expressed polyreactive anti-
bodies at a higher frequency than control new emigrant B
cells but without reaching statistical significance (RA02:
25.0%, P   0.07 and RA03: 18.5%, P   0.16; Fig. 4 A).
The frequency of polyreactive antibodies was also increased
in the mature naive B cell compartment of five out of six
RA patients and reached significance for three of them
(RA01: 25%, P   0.006; RA05: 30%, P   0.004; RA06:
27.6%, P   0.0023; Fig. 4 B). Thus, most RA patients fail to
efficiently remove polyreactive B cells and reveal defects at
the early B cell tolerance checkpoint in the bone marrow.
Presence of naive B cells reactive to Ig and CCP 
in RA patients
Igs and CCP are the most common autoantigens in RA (2, 4,
5). Five out of six of our RA patients showed elevated anti-
CCP antibody levels in their serum and only RA01 was
rheumatoid factor negative (Table I). To determine if naive
RA B cells can recognize IgG and CCP, we used ELISAs to
analyze the rheumatoid factor and anti-CCP reactivity of re-
combinant antibodies from new emigrant and mature naive B
cells. We found that new emigrant B cells from RA01 and
RA04 expressed a higher proportion of rheumatoid factors
(RA01: 34.6%, P   0.027 and RA04: 30.2%, P   0.046 vs.
9.7% in controls; Fig. 5 A). RA02, RA03, and RA05 new
emigrant B cells also express rheumatoid factors at a higher
frequency than control new emigrant B cells but without
reaching statistical significance (RA02: 25.0%, P     0.21;
RA03: 18.5%, P   0.45; and RA05: 21.4%, P   0.22; Fig. 5
A). The percentage of B cells expressing rheumatoid factors
was still found elevated in the naive B cell compartment of
RA01, RA04, RA05, and RA06 (Fig. 5 B). Most of the anti-
bodies that showed rheumatoid factor reactivity in either
controls or patients were not specific for IgG but also recog-
nized single-stranded DNA, double-stranded DNA, insulin,
and LPS and were therefore polyreactive (Table S2 available
at http://www.jem.org/cgi/content/full/jem.20042321/
DC1). Similarly to rheumatoid factors, the proportion of
anti-CCP antibodies was increased in RA new emigrant B
cells, and the differences with controls reached significance
Figure 3. Increased frequency of HEp-2–reactive antibodies in 
mature naive B cells from RA patients. Data shown are from ELISAs for 
anti–HEp-2 cell reactivity of recombinant antibodies cloned from (A) new 
emigrant and (B) mature naive B cells from RA patients. Dotted lines show 
ED38 positive control (13, 17). The percentage of autoreactive clones for 
each fraction and their p-values for differences with controls are indi-
cated. *, The controls for new emigrant and mature naive B cells isolated 
from HD01, HD02, HD03, and HD04 were previously reported (13, 14).
Figure 4. RA B cells express polyreactive antibodies. Antibodies 
from (A) new emigrant and (B) mature naive B cells from RA patients were 
tested by ELISAs for reactivity with single-stranded DNA (ssDNA), double-
stranded DNA (dsDNA), insulin, and lipopolysaccharide (LPS). Dotted lines 
show ED38-positive control (13, 17). Percentages represent frequency of 
polyreactive antibodies in each fraction. *, The controls for new emigrant 
and mature naive B cells isolated from HD01, HD02, HD03, and HD04 were 
previously reported (13, 14).JEM VOL. 201, May 16, 2005 1663
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for half of the patients (RA01: 19.2%, P   0.016; RA03:
14.8%, P   0.041; and RA04: 14.0%, P   0.037; Fig. 5 C).
The percentage of anti-CCP antibodies remained elevated
and ranged from 10 to 17.9% in the mature naive B cell com-
partments of RA patients (Fig. 5 D). Anti-CCP antibodies
showed low levels of reactivity when compared with serum
anti-CCP IgG antibodies from positive controls (Fig. 5, C
and D). Most of the antibodies that reacted to CCP were in
fact polyreactive antibodies (Tables S2–S13 available at http:
//www.jem.org/cgi/content/full/jem.20042321/DC1). How-
ever, none of the polyreactive antibodies from healthy indi-
viduals recognized CCP (Fig. 5 C). We conclude that a frac-
tion of new emigrant and mature naive B cells from RA
patients express polyreactive antibodies that can recognize
RA-specific antigens IgG and CCP with low affinity.
RA antibodies with unusual  11–amino acid–long Ig  
CDR3s are frequently self-reactive
The proportion of B cells expressing antibodies with unusual
 11–amino acid–long Ig  CDR3s is increased in most RA
patients (11, 12). We analyzed the reactivity of those unusual
clones and found that most antibodies containing  11–
amino acid–long CDR3 Ig  chains were either HEp-2–
reactive and/or polyreactive (77.8%, 14 out of 18; Table II).
The frequency of autoreactivity for RA antibodies with
shorter Ig  CDR3s was lower and averaged 48.8% (126/
258; Tables S2–S13 available at http://www.jem.org/cgi/
content/full/jem.20042321/DC1). In addition, B cells that
express  11–amino acid–long Ig  chains preferentially used
V 3-11–variable gene that was found in almost half (8/18)
of these unusually long Ig  chains whereas V 3-11–variable
gene only accounted for 0–11.1% and 0–17.4% of control
and RA Ig  chains with shorter CDR3s, respectively (Table
II and Tables S2–S20 available at http://www.jem.org/cgi/
content/full/jem.20042321/DC1). Thus, a majority of pe-
ripheral B cells expressing unusual antibodies with  11–
amino acid–long Ig  CDR3s are autoreactive and contribute
to the enlarged compartment of peripheral self-reactive B
cells in some RA patients.
DISCUSSION
Autoreactive B cells generated during bone marrow B cell
development fail to be counterselected in RA patients. De-
spite the broad age range (28–64 yr old) and duration of dis-
ease (1–13 yr), all six patients show similarly elevated per-
centages of autoreactive mature naive B cells that differ from
those of six adult control donors previous reported (23–40 yr
old; 13, 14, 17). The first B cell tolerance checkpoint that
normally removes most polyreactive B cells in the bone mar-
row is defective in RA patients, as reflected by the increased
percentage of polyreactive B cells in their new emigrant B
cell compartment (13). Most polyreactive antibodies enriched
in RA peripheral B cells are also reactive with RA-specific
antigens and show low rheumatoid factor and anti-CCP re-
activity. This early break in B cell tolerance may explain why
RA patients relapse after successful treatment with anti-CD20
monoclonal antibodies that target immature and mature B
cells but not their precursors (10). The second peripheral
checkpoint that accounts for additional removal of autoreac-
tive B cells in the periphery between the new emigrant and
the mature naive B cell stage is also defective, and allows the
accumulation of a large number of self-reactive B cells in the
mature naive B cell compartment of all RA patients.
What are the defective mechanisms that may be respon-
sible for the early break in B cell tolerance in RA patients?
The biased repertoires observed in our RA patients were
found in new emigrant B cells and may reflect abnormal
bone marrow B cell development. In the mouse, three cen-
tral mechanisms are responsible for self-reactive antibody si-
lencing: deletion, anergy, and receptor editing (18–22).
Light chain antibody sequences from RA01, RA02, and
RA08 patients showed an increase in downstream V  genes
associated with the most upstream J , J 1, suggesting ineffi-
cient secondary recombination and therefore a potential de-
fect in receptor editing. Consistent with our data, defects in
secondary recombination have also been reported in other
rheumatic diseases such as systemic lupus erythematosus
Figure 5. RA peripheral B cells contain rheumatoid factor and 
anti-CCP clones. Antibodies from new emigrant and mature naive B cells 
from RA patients were tested by ELISAs for reactivity against IgG (A and B) 
and CCP (C and D). Dotted lines show either ED38-positive control (A and 
B) or serum anti-CCP IgG-positive control (C and D). Percentages repre-
sent frequency of anti-CCP antibodies in each fraction. P-values are in 
comparison to control new emigrant B cells (13, 14).DEFECTIVE COUNTERSELECTION OF AUTOREACTIVE B CELLS IN RA PATIENTS | Samuels et al. 1664
(SLE) and may therefore account for the increased frequency
of polyreactive and autoreactive B cells in the periphery (23,
24). In contrast, Ig  chains from RA06 new emigrant B cells
showed an increase in upstream V  genes associated with
downstream J s suggesting extensive secondary recombina-
tion in those cells. Interestingly, extensive secondary recom-
bination has also been reported in B cells from an untreated
SLE patient and suggests that it can be an abnormal mecha-
nism shared by different rheumatic diseases (25). BCR sig-
naling plays an important role in controlling receptor editing
by regulating recombination activating genes in mice and in
humans (14, 26–28). Defects in BCR signaling may result
either in a failure to induce receptor editing or in a prema-
ture termination of secondary recombination at the imma-
ture B cell stage. Alternatively, other BCR signaling defects
may fail to terminate secondary recombination. X-linked
agammaglobulinemia (XLA) patients suffer from defective
BTK genes, which encode a cytoplasmic tyrosine kinase that
plays an essential role in mediating BCR signaling (29, 30).
We recently reported that XLA B cells showed extensive
secondary recombination events and expressed autoreactive
BCRs thereby demonstrating that proper BCR signaling is
essential in regulating thresholds for human B cell tolerance
(14). Little is known about BCR signaling defects in RA B
cells, but abnormal BCR signaling has been reported in SLE
B cells that also suffer from defective B cell tolerance (31,
32). More recently, a missense polymorphism in the protein
tyrosine phosphatase PTPN22 gene have been shown to
segregate with RA and SLE patients (33, 34). This missense
polymorphism in PTPN22 disrupts its interaction with Csk
tyrosine kinase and potentially alters these proteins’ normal
function as regulators of BCR signaling (33).
Patients RA03, RA04, RA05, RA07, and RA09 do not
show any significant evidence of defective secondary recom-
Table II.  RA antibodies with 11- and 12-amino acid-long Ig  CDR3s are frequently autoreactive
Ig
Heavy Light Reactivity
VH D RF JH CDR3 (aa) Length V  J  CDR3 (aa) Length ssDNA dsDNA Insulin LPS IgG CCP HEp-2
RA01 10  180 3-74 5-12 2 4 ARDPPEALSGYDW
DPYYFDY
20 3-11 2 QQRSNWPPGYT 11            
RA02 10  08 3-43 / / 4 AKD-
DDDRYPSWGLLDY
16 3-11 3 QQRSNWPPPFT 11            
RA02 10  21 3-30 3-22 2 4 ARERDYYDSSG-
FDY
14 1-9 2 QQLNSYPYMYT 11            
RA03 10  01 3-21 / / 4 ARSRGITVDDY 11 1-5 4 QQYNSYSPSFT 11            
RA03 10  27 3-66 3-3 2 4 ARGSGENYDFWS-
VPFDY
17 3-11 1 QQRSNWPPTWT 11            
RA03 10  56  3-7 3-9 1 4 ARDGVLRYFD-
WLFHRFDY
18 3-11 2 QQRSNWPPY-
MYT
12            
RA03 10  67 3-11 / / 4 ARGDLAHPTDY 11 3-15 2 QQYNNWPRMYT 11            
RA03 10  77 3-73 4-17 2 6 TRRLDDYGDYGV-
VSHYYYYGMDV
23 1-33 3 QQYDNLPPIFT 11            
RA04 10  21 3-23 2-15 2 4 ARFLVLGYC-
SGGSCYTFDY
19 1-5 1 QQYNSYSRAWT 11            
RA04 10  53 3-53 2-2 3 6 ARGRDIV-
VVPAAIVYYGMDV
20 1-5 2 QQYNSYSPMCS 11            
RA04 10  83 3-15 5-5 2 6 TTAGEPGYSY-
LYYYYGMDV
19 3-11 4 QQRSNWPPGLT 11            
RA05 10  39 1-69 1-7 3 4 ASITGTLN 8 1-5 1 QQYNSYSPTWT 11            
RA05 10  57 1-46 2-15 2 4 ARDFSERYC-
SGGSCYSEFDY
20 3-11 4 QQRSNWPLALT 11            
RA06 10  70 3-21 3-16 2 3 ARGSAQRSEY-
DYVWGSYR-
PLDAFDI
25 3-11 5 QQRSNWPPEVT 11            
RA06 10  181 3-11 3-22 3 5 ARSMIVVVPPPG-
FDP
15 1-33 2 QQYDNLPPLYT 11            
RA01 10  60 1-69 5-24 2 4 ARGDGGGDH-
PFFDY
14 3-15 2 QQYNNWPPLYT 11            
RA06 10  92 3-53 / / 4 AREPLGSPGFDY 12 1-9 3 QQLNSYPPQFT 11            
RA06 10  95 3-53 2-21 2 4 AHGDCYFDY 9 3-11 3 QQRSNWPPLFT 11            
Sequence features and reactivity of antibodies with 11– and 12–amino acid–long Igk CDR3s from new emigrant (10 ) and mature naive (10 ) B cells from RA patients. 
RF, reading frame.JEM VOL. 201, May 16, 2005 1665
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bination, illustrating the heterogeneity of rheumatic diseases.
However, those RA patients like others showed an increased
proportion of new emigrant B cells expressing  11–amino
acid–long CDR3 Ig  chains (11, 12). Interestingly,  11–
amino acid–long CDR3 Ig s were enriched in new emi-
grant B cells but not in mature naive B cells. The disappear-
ance of those unusual clones from the mature naive B
compartment in the peripheral blood may reflect a coun-
terselection step still functional in RA patients. Alternatively,
B cells expressing  11–amino acid–long CDR3 Ig s may
not be counterselected but migrate to the joints of RA pa-
tients where they accumulate (12). In line with this hy-
pothesis, antibodies with  11–amino acid–long CDR3 Ig s
were frequently found to be self-reactive and may recognize
joint antigens. The production of 11–amino acid–long
CDR3 Ig  chains mostly requires the addition of nontem-
plate nucleotides to V–J junctions by the terminal deoxynu-
cleotidyl transferase (TdT) whose expression is normally
down-regulated by preBCR expression at the preB cell stage
(35, 36). Abnormal BCR signaling may fail to down-regu-
late TdT expression and may therefore result in the genera-
tion of those 11–amino acid–long CDR3 Ig  chains as re-
ported in some XLA patients (14, 37). Alternatively, light
chain gene rearrangements at the pro-B cell stage when TdT
is expressed may generate 11–amino acid–long CDR3 Ig 
chains found in RA patients (38).
Autoreactive B cells that escape central B cell tolerance
are normally counterselected in the periphery and fail to en-
ter the long-lived mature naive B cell pool (39, 40). The ap-
pearance of autoreactive B cells in the periphery of RA pa-
tients may result from either defective negative or abnormal
positive selection processes that are believed to control pe-
ripheral B cell tolerance (41–43). Interestingly, serum BAFF
levels have been recently shown to regulate autoreactive B
cell deletion by rescuing self-reactive B cells from cell death
(44, 45). Patients with rheumatic diseases including RA have
been reported to display elevated BAFF serum levels that
may therefore result in the survival of unusual autoreactive B
cell clones in the blood of RA patients (46).
How could mature naive autoreactive B cells contribute
to RA? A large number of mature naive B cells from RA pa-
tients express autoreactive and polyreactive antibodies that
can recognize classical RA autoantigens with low affinity. A
recent report showed that similar autoreactive/polyreactive
mature naive B cells accumulated in the periphery of SLE
patients (32). Genetic and environmental factors may select
and activate those autoreactive/polyreactive mature naive B
cells in a differential manner in RA and SLE patients. This
would allow the development of B cells secreting isotype-
switched antibodies with high affinity to self-antigens spe-
cific for either RA or SLE. For instance, polyreactive B cells
that recognize Igs may bind IgG–chromatin immune com-
plexes in the joints of RA patients. Dual engagement of
BCR and toll-like receptors such as TLR9 may activate such
B cells and induce their development into rheumatoid fac-
tor–producing B cells (47, 48). Polyreactive RA B cells
that recognize CCP may bind and internalize citrullinated
peptides that can interact with RA-associated HLA-
DRB1*0401 MHC class II molecules and activate specific
autoreactive T cells (49). In return, those T cells would pro-
vide activation signals to CCP-reactive B cells and induce
their proliferation and eventually the formation of ectopic
germinal centers, resulting in the production of specific high
affinity anti-CCP autoantibodies (50, 51).
In conclusion, the antibody repertoire heterogeneity of
our RA patients reflects different defective mechanisms of B
cell tolerance resulting from potentially diverse RA genetic
polymorphisms. Yet all six patients showed defective tolerance
checkpoints and the presence of a reservoir of self-reactive
mature naive B cells, likely contributing to RA pathogenesis.
MATERIALS AND METHODS
Patients. Patient 1 (RA01) is a 60-yr-old black woman who was diag-
nosed with RA in 1990 with symmetric polyarticular symptoms and severe
morning stiffness. We first met her after 13 yr of intermittent treatment
with steroids, hydroxychloroquine, and methotrexate but she had no treat-
ments in the previous 5 mo (Table I). Initial data included an erythrocyte
sedimentation rate of 127, a negative rheumatoid factor ( 20), a slight ele-
vation in anti-CCP titer (32), and multiple erosions on radiographs. Patient
2 (RA02) is a 62-yr-old Asian man who presented with 2 yr of increasing
right shoulder, left elbow and bilateral wrist/hand pains, and years of in-
creasing right knee pain. His medications at presentation were celecoxib,
atenolol, and omeprazole. Data were significant for an erythrocyte sedimen-
tation rate of 14 but elevated levels of rheumatoid factor (848) and anti-
CCP antibodies (88), and radiographs with erosions and an effusion in the
left elbow, and erosions in the right wrist and left IP joints. Patient 3
(RA03) is a 62-yr-old Hispanic woman who presented 3 yr prior with sym-
metrical polyarticular joint swelling/pain and morning stiffness, and a diag-
nostic work up consistent with RA. Treated intermittently with methotrex-
ate and steroids, she stopped all of her medications 4 mo before the most
recent flare because she was feeling well and presented with severe pain and
swelling in both her upper and lower extremities. Medications on presenta-
tion included Prevacid and naproxen. Significant data included high titers of
rheumatoid factor (1,110) and anti-CCP antibodies (240), and normal ra-
diographs. Patient 4 (RA04) is a 36-yr-old white woman who presented
with 1 yr of increasing pain and morning stiffness in her hands and elbows,
but had refused all treatment. Workup included elevated levels of rheuma-
toid factor (55) and anti-CCP antibodies (63) but no radiographic erosions.
Patient 5 (RA05) is a 30-yr-old white woman who presented with 2 yr of
increasing left wrist and ankle pain and swelling, but had not taken any
medication. Data included an elevated rheumatoid factor (48) but an anti-
CCP antibody titer  20, with erosions (only seen with MRI) in both
joints. Patient 6 (RA06) is a 64-yr-old black woman who presented with 2
yr of increasing pain and swelling in the right hand and shoulder, and poly-
articular arthralgias, but had not been on any medication. Data included
elevated titers of rheumatoid factor (474) and anti-CCP antibodies ( 250),
but no radiographic erosions. Patient 7 (RA07) is a 44-yr-old black woman
who presented with 2 yr of increasing pain and swelling in her hands and
knees, and had not improved while on hydroxychloroquine for 2 mo. Data
included elevated titers of rheumatoid factor (267) and anti-CCP antibodies
(218), but no radiographic erosions. Patient 8 (RA08) is a 28-yr-old His-
panic male who first presented 2 yr prior with morning stiffness and sym-
metrical swelling of the hands, wrists, knees and ankles, and responded well
to steroids, methotrexate, and hydroxychloroquine. He stopped the medi-
cation 10 mo before representing with 2 wk of polyarticular arthritis more
severe than on initial presentation, with elevated titers of rheumatoid factor
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(RA09) is a 52-yr-old Hispanic female who presented with 1 yr of pain and
swelling in her hands, wrists, knees, and ankles, but had received no medi-
cation. Data included elevated titers of rheumatoid factor (36) and anti-
CCP antibodies (150), and erosions of her MCPs by ultrasound.
We analyzed three additional healthy donors (HD05, 57; HD06, 60;
and HD07, 48) and further investigated the four previously reported control
healthy donors (HD01 [GO] 23; HD02 [JB] 24; HD03 [JH] 24, and HD04
[PE] 31 yr old; Table S1; 13, 14). All samples were collected after patients
signed informed consent in accordance with IRB-reviewed protocols.
Single cell sorting. Peripheral B cells were purified from the blood of
RA patients by negative selection using RosetteSepTM procedure (StemCell
Technologies Inc.). New emigrant B cells were further enriched by positive
selection with anti-PE magnetic microbeads (Miltenyi Biotech) after PE
anti–human CD10 staining (BD Biosciences). CD10-enriched and CD10-
depleted peripheral B cells from RA patients were stained with FITC anti–
human CD27, anti–human IgM-Biotin, and APC anti–human CD19 (BD
Biosciences). Biotinylated antibodies were revealed using PE-cy7–conju-
gated streptavidin (BD Biosciences). Single CD19 CD10 IgM CD27 
new emigrant and CD19 CD10 IgM CD27  mature naive B cells were
sorted on a FACSVantage (Becton Dickinson) into 96-well PCR plates
containing 4  l lysis solution (0.5  PBS containing 10 mM DTT, 8 U
RNAsin (Promega), 0.4 U 5 –3  RNase inhibitor (Eppendorf), and imme-
diately frozen on dry ice. All samples were stored at –70 C.
cDNA, RT-PCR, antibody production, and purification. RNA
from single cells was reverse transcribed in the original 96-well plate in 12.5
 l reactions containing 100 U of Superscript II RT (GIBCO BRL) for 45
min at 37 C. RT-PCR reactions, primer sequences, cloning strategy, ex-
pression vectors, antibody expression, and purification were as described
(13). Ig sequences were analyzed by Ig BLAST comparison with GenBank/
EMBL/DDBJ. Heavy chain CDR3 was defined as the interval between the
conserved cysteine at position 92 in the VH framework 3 and the conserved
tryptophan at position 103 in JH segments.
ELISAs and IFAs. Antibody concentration, reactivity against specific an-
tigens, and IFAs were as described previously (13). High (polyreactive
ED38) and weak (mGO186) HEp2-reactive and -nonreactive mGO53 and
iGO13 were used as positive and negative controls in HEp2-reactivity and
polyreactivity ELISAs (13, 17). Those control antibodies established that re-
combinant antibodies with absorbance values above 0.4 could be considered
reactive with the coated antigen. Antibodies were polyreactive when they
recognized at least two and usually all of the four analyzed antigens that in-
clude single-stranded DNA, double-stranded DNA, insulin, and LPS.
Rheumatoid factor reactivity was determined by ELISA using rabbit whole
IgG as antigens and recombinant antibody binding was revealed using per-
oxidase-conjugated rabbit anti–human IgG (Jackson ImmunoResearch Lab-
oratories, Inc.). Anti-CCP reactivity was determined using QUANTA
LiteTM CCP ELISA plates (INOVA Diagnostics, Inc.).
Statistical analysis. Fisher exact tests were used to analyze dichotomized
data. J s were dichotomized into J 1, the most upstream of all J s used in
primary recombination events, versus all the other J s whose usage may in-
volve secondary recombination events. Student’s t tests were used to analyze
the differences in proportions of  11–amino acid–long Ig  CDR3s be-
tween healthy donors and RA patients. All statistical tests were considered
two-tailed and probability values of P   0.05 were considered to be statisti-
cally significant.
Online supplemental material. Healthy donor characteristics are shown
in Table S1. Antibody characteristics from RA patients and control B cells
are presented in Tables S2–S20. Online supplemental material is available at
http://www.jem.org/cgi/content/full/jem.20042321/DC1.
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